MX2018007776A - Formas polimorficas cristalinas del acido obeticolico. - Google Patents

Formas polimorficas cristalinas del acido obeticolico.

Info

Publication number
MX2018007776A
MX2018007776A MX2018007776A MX2018007776A MX2018007776A MX 2018007776 A MX2018007776 A MX 2018007776A MX 2018007776 A MX2018007776 A MX 2018007776A MX 2018007776 A MX2018007776 A MX 2018007776A MX 2018007776 A MX2018007776 A MX 2018007776A
Authority
MX
Mexico
Prior art keywords
crystalline forms
obeticholic acid
polymorphic crystalline
disease
useful
Prior art date
Application number
MX2018007776A
Other languages
English (en)
Spanish (es)
Inventor
Steiner André
Waenerlund Poulsen Heidi
Jolibois Emilie
Rewolinski Melissa
Gross Ralf
Sharp Emma
Dubas-Fisher Fiona
Eberlin Alex
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018007776(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/979,005 external-priority patent/US9982008B2/en
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2018007776A publication Critical patent/MX2018007776A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018007776A 2015-12-22 2016-01-08 Formas polimorficas cristalinas del acido obeticolico. MX2018007776A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/979,005 US9982008B2 (en) 2012-06-19 2015-12-22 Preparation and uses of obeticholic acid
PCT/US2016/012651 WO2017111979A1 (en) 2015-12-22 2016-01-08 Polymorphic crystalline forms of obeticholic acid

Publications (1)

Publication Number Publication Date
MX2018007776A true MX2018007776A (es) 2018-08-09

Family

ID=55650649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007776A MX2018007776A (es) 2015-12-22 2016-01-08 Formas polimorficas cristalinas del acido obeticolico.

Country Status (15)

Country Link
EP (1) EP3394081A1 (ja)
JP (1) JP2018538331A (ja)
KR (1) KR20180095070A (ja)
CN (1) CN108495858A (ja)
AU (1) AU2016375566A1 (ja)
BR (1) BR112018012590A2 (ja)
CA (1) CA3009149A1 (ja)
CL (1) CL2018001720A1 (ja)
CO (1) CO2018006701A2 (ja)
EA (1) EA201891491A1 (ja)
IL (1) IL259998A (ja)
MX (1) MX2018007776A (ja)
PH (1) PH12018501318A1 (ja)
SG (1) SG11201805235XA (ja)
WO (1) WO2017111979A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CN109280071A (zh) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 奥贝胆酸的晶型及其制备方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CZ31099U1 (cs) * 2017-09-05 2017-10-17 Zentiva, K.S. Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN113264972A (zh) * 2020-02-14 2021-08-17 四川科伦药物研究院有限公司 一种制备奥贝胆酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
IN2014MN02561A (ja) * 2012-06-19 2015-09-04 Intercept Pharmaceuticals Inc
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
ES2759725T3 (es) * 2014-11-19 2020-05-12 Nzp Uk Ltd Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediarios para la producción de moduladores de FXR esteroideo
ES2748692T3 (es) * 2014-11-19 2020-03-17 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
ES2733643T3 (es) * 2014-11-19 2019-12-02 Nzp Uk Ltd Esteroides 5.beta.-6-alquil-7-hidroxi-3-ona como intermedios para la producción de moduladores FXR de esteroides
JP6698085B2 (ja) * 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド

Also Published As

Publication number Publication date
IL259998A (en) 2018-07-31
PH12018501318A1 (en) 2019-02-18
WO2017111979A1 (en) 2017-06-29
EA201891491A1 (ru) 2018-11-30
CO2018006701A2 (es) 2018-07-10
AU2016375566A1 (en) 2018-07-05
SG11201805235XA (en) 2018-07-30
KR20180095070A (ko) 2018-08-24
CL2018001720A1 (es) 2018-08-10
BR112018012590A2 (pt) 2018-12-04
CA3009149A1 (en) 2017-06-29
JP2018538331A (ja) 2018-12-27
CN108495858A (zh) 2018-09-04
EP3394081A1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
PH12018501318A1 (en) Polymorphic crystalline forms of obeticholic acid
PH12014502835A1 (en) Preparation, uses and solid forms of obeticholic acid
HUS2200011I1 (hu) Készítmények és eljárások HAO1 (hidroxisav-oxidáz-1 (glikolát-oxidáz)) gén expressziójának gátlására
HUS2100041I1 (hu) Eljárások és kompozíciók a glikolát-oxidáz (HAO1) kettõs szálú RNA általi specifikus gátlására
HRP20190270T1 (hr) C1-inh pripravci i postupci za prevenciju i liječenje poremećaja povezanih s nedostatkom inhibitora c1 esteraze
EP3174550A4 (en) Methods and compositions relating to treatment of pulmonary arterial hypertension
GB2551964B (en) Method of treating biomass to remove RNA
EP3363783A4 (en) COMPOSITION FOR THE TREATMENT OF INFLAMMATORY ENDURANCE AND ATOPIC DERMATITIS
EP3370714A4 (en) COMPOSITIONS AND METHODS FOR TREATING FATTY ACID METABOLISM DISORDERS
MX2016015577A (es) La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal.
EP3251675A4 (en) Prevention or treatment of uric acid or gout disease
AU2010904366A0 (en) Method of treating disorders using magnesium